ADA and cancer: In a focused review consolidating immunogenicity data from 81 clinical trials with anti-cancer biologics, Van Brummelen and colleagues observed that 63% of these studies report ADA formation (10), suggesting that many compounds currently being investigated in oncology are potentially immunogenic.